Pablo J. Cagnoni, M.D. has been promoted to vice president and chief medical officer, OSI Pharmaceuticals, Inc. In this position, Dr. Cagnoni will oversee all of the clinical development and medical affairs activities of the company's oncology portfolio, which includes further development of Tarceva. Dr. Cagnoni has also been appointed as an officer of the corporation and will serve as a member of the company's executive management committee.

"Pablo has shown excellent leadership in managing Tarceva's development program as well as the company's oncology clinical operations during his tenure," stated Colin Goddard, chief executive officer of OSI Pharmaceuticals. "As the company continues to build a top-tier oncology franchise upon the success of Tarceva, Pablo's expertise in oncology will play an integral role in advancing innovative molecular targeted therapies within our pipeline."

Dr. Cagnoni has 20 years of clinical development experience in oncology in both biotechnology and academic settings. He previously served as vice president, clinical development and medical affairs at OSI. Before joining the company in 2004, Dr. Cagnoni was vice president of clinical development at Allos Therapeutics, where he headed the development organization and led the development of Efaproxyn and pralatrexate. Prior to that, Dr. Cagnoni was assistant professor of medicine in the Division of Oncology at the University of Colorado. Dr. Cagnoni has authored more than 50 publications, numerous book chapters and has lectured extensively in several areas related to clinical oncology and drug development.

News from our sister sites